EP9-IPO 不是終點，而是定價的開始？生技公司何時值得被市場買單 The IPO Timing Equation

【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

當一間生技公司可以上市，是否就代表成功已經確定？
當投資人說在「看故事」，法人其實在看的是什麼？
當臨床數據逐步揭露，誰在決定估值的上限與下限？
本集我們邀請到漢康生技財務長——曾木增 Alan，拆解 IPO 背後的資本邏輯與風險管理思維。

精彩內容：

IPO 時機的本質：為什麼生技公司不是「能不能上」，而是「何時上最划算」？
法人視角的五大條件：當市場看故事，為什麼機構投資人只看「可被定價的不確定性」？
估值驅動因子解析：臨床進度、BD 授權與 Pipeline，如何構成股價的核心引擎？
資本與控制權的平衡：如何在募資、稀釋與公司治理之間維持戰略主導權？
CFO 的風險地圖：從臨床、現金流到商業化，如何將不確定性轉化為可管理的決策節點？

【About This Episode】
When is a biotech company truly ready for IPO—not just to list, but to be valued?
If retail investors see “a story,” what do institutional investors actually price in?
And after going public, what really drives valuation—data, deals, or discipline?
In this episode, Alan Tseng, CFO of HanchorBio, breaks down the financial logic behind IPO timing, valuation frameworks, and post-listing strategy.
From clinical milestones and BD execution to capital efficiency and governance design, this conversation reveals how biotech companies transform scientific uncertainty into market-priced assets.
IPO is not the finish line—it is the moment when uncertainty becomes measurable, and growth becomes tradable.

【Key Takeaways】
The Timing Equation of IPO: Why is the optimal IPO window a balance between de-risking and remaining upside?
What Institutions Really Evaluate: How do investors determine whether uncertainty has been reduced enough to price?
Valuation Drivers Post-IPO: Why clinical milestones, licensing deals, and pipeline depth dominate market valuation?
Capital vs. Control: How do biotech firms balance fundraising needs with strategic control and governance?
The CFO’s Risk Framework: How are clinical uncertainty, financial exposure, and commercialization risks quantified and managed?

漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。